Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it has entered into an exclusive license agreement with The Regents of the University of California. As quoted in the press release: Under the agreement, the Company has … Continued